Zogenix Inc (NASDAQ:ZGNX) Shorts Strengthened By 19.25%

Zogenix, Inc. (NASDAQ:ZGNX) Corporate Logo

Zogenix Inc (NASDAQ:ZGNX) had an increase of its short interest by 19.25%. In December was published ZGNX’s total 5.36 million short interest by FINRA. Previously was reported up change of 19.25% from 4.50M shares. Previous ZGNX’s position will need 8 days to recover. It has 677,000 average volume. 18.92% is Zogenix Inc float short.

The stock decreased 2.43% or $1.06 during the last trading session, reaching $42.55.Zogenix, Inc. has 552,741 shares volume, 0.57% up from normal. ZGNX is uptrending and has moved 209.29% since December 8, 2017. The stock outperformed the S&P500 by 193.67%.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States.The firm is valued at $1.79 billion. The companyÂ’s lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.Last it reported negative earnings. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.

Zogenix, Inc. (NASDAQ:ZGNX) Ratings Coverage

A total of 5 analysts rate Zogenix (NASDAQ:ZGNX) as follows: 5 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:ZGNX) has 5 ratings reports on Dec 8, 2018 according to StockzIntelligence. On Friday, July 13 Stifel Nicolaus maintained the shares of ZGNX in report with “Buy” rating.

For more Zogenix, Inc. (NASDAQ:ZGNX) news published recently go to: Globenewswire.com, Seekingalpha.com, Fool.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Zogenix Provides Corporate Update and Reports Third Quarter Financial Results – GlobeNewswire” published on November 08, 2018, “Premarket analyst action – healthcare – Seeking Alpha” on September 07, 2018, “Is This the Biggest Threat to GW Pharmaceuticals’ Marijuana Drug? – The Motley Fool” with a publish date: September 27, 2018, “Noteworthy Monday Option Activity: ZGNX, NTNX, AFSI – Nasdaq” and the last “Zogenix Welcomes New Global Chief Commercial Officer – GlobeNewswire” with publication date: July 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.